EZH2 and lung carcinoma: The oncogenic role of EZH2 in lung cancer was now clearly demonstrated by all these works, and several EZH2 inhibitors under clinical trials exhibited potential to be applied as novel targeted therapy or as an aid to current drug therapy for lung cancer (more detailed discussion in 5.1, 5.2) [60, 61].